Program
RCI001
A development code. Also written as “RCI001 Eye Drops 0.25%”, “RCI001 Ophthalmic Solution” and “0.25% RCI001 Ophthalmic Solution”.
Its studies are mostly in Dry Eye Syndromes, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rudacure | 21 open or running | phase 2since May 12, 2026 | May 12, 2026 | Jun 30, 2028phase 2 · NCT07625124 |
| ORA | 11 open or running | phase 2since Jun 27, 2025 | Jun 27, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2025First study: phase 2 study in Dry Eye SyndromesNew to ORAORA · NCT07068958 · 200 planned
- May 12, 2026Rudacure's first study: phase 1 study in Dry Eye SyndromesNew to RudacureRudacure · NCT07640867 · 40 enrolled · South Korea
- May 12, 2026Phase 2 study in Dry Eye SyndromesRudacure · NCT07625124 · 200 planned
Ahead
- Jun 30, 2028Primary completion: phase 2 study in Dry Eye SyndromesRudacure · NCT07625124
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07640867Dry Eye Syndromes · South Korea | 1 | Completed | Rudacure | Aug 29, 2025 | 40 |
| NCT07625124Dry Eye Syndromes | 2 | Not yet recruiting | Rudacure | Jun 30, 2028 | 200 |
| NCT07068958Dry Eye Syndromes | 2 | Not yet recruiting | ORA | Nov 1, 2025 | 200 |
How it is read
Names in the registry
- “RCI001 Eye Drops 0.25%”, 1 entry
- “RCI001 Ophthalmic Solution”, 1 entry
- “0.25% RCI001 Ophthalmic Solution”, 1 entry
Codes read as this program: RCI001.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.